Nod2 Protects the Gut From Experimental Colitis Spreading to Small Intestine.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
19 Jun 2020
Historique:
pubmed: 1 12 2019
medline: 15 4 2021
entrez: 1 12 2019
Statut: ppublish

Résumé

Nucleotide oligomerization domain 2 [NOD2] mutations are key risk factors for Crohn's disease [CD]. NOD2 contributes to intestinal homeostasis by regulating innate and adaptive immunity together with intestinal epithelial function. However, the exact roles of NOD2 in CD and other NOD2-associated disorders remain poorly known. We initially observed that NOD2 expression was increased in epithelial cells away from inflamed areas in CD patients. To explore this finding, Nod2 mRNA expression, inflammation, and cytokines expression were examined in the small bowel of wild-type [WT], Nod2 knockout and Nod2 mutant mice after rectal instillation of 2,4,6-trinitrobenzene sulphonic acid [TNBS]. In WT mice, Nod2 upregulation upstream to rectal injury was associated with pro-inflammatory cytokine expression but no overt histological inflammatory lesions. Conversely, in Nod2-deficient mice the inflammation spread from colitis to ileum and duodenum. Nod2 protects the gut from colitis spreading to small intestine.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Nucleotide oligomerization domain 2 [NOD2] mutations are key risk factors for Crohn's disease [CD]. NOD2 contributes to intestinal homeostasis by regulating innate and adaptive immunity together with intestinal epithelial function. However, the exact roles of NOD2 in CD and other NOD2-associated disorders remain poorly known.
METHODS METHODS
We initially observed that NOD2 expression was increased in epithelial cells away from inflamed areas in CD patients. To explore this finding, Nod2 mRNA expression, inflammation, and cytokines expression were examined in the small bowel of wild-type [WT], Nod2 knockout and Nod2 mutant mice after rectal instillation of 2,4,6-trinitrobenzene sulphonic acid [TNBS].
RESULTS RESULTS
In WT mice, Nod2 upregulation upstream to rectal injury was associated with pro-inflammatory cytokine expression but no overt histological inflammatory lesions. Conversely, in Nod2-deficient mice the inflammation spread from colitis to ileum and duodenum.
CONCLUSIONS CONCLUSIONS
Nod2 protects the gut from colitis spreading to small intestine.

Identifiants

pubmed: 31784737
pii: 5648102
doi: 10.1093/ecco-jcc/jjz196
doi:

Substances chimiques

NOD2 protein, human 0
Nod2 Signaling Adaptor Protein 0
Nod2 protein, mouse 0
RNA, Messenger 0
Tumor Necrosis Factor-alpha 0
Interleukin-12 187348-17-0
Interferon-gamma 82115-62-6
Trinitrobenzenesulfonic Acid 8T3HQG2ZC4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

669-679

Informations de copyright

Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Ziad Al Nabhani (Z)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.

Dominique Berrebi (D)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.
Hopital Robert Debré, Asssitance Publique Hôpitaux de Paris, Paris, France.

Christine Martinez-Vinson (C)

Hopital Robert Debré, Asssitance Publique Hôpitaux de Paris, Paris, France.

Nicolas Montcuquet (N)

Laboratoire d'immunité intestinale, Paris, France.
Université Paris Descartes - Sorbonne Paris Cité, Institut IMAGINE, Paris, France.

Chrystele Madre (C)

Hopital Robert Debré, Asssitance Publique Hôpitaux de Paris, Paris, France.

Maryline Roy (M)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.

Eric Ogier-Denis (E)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.

Monique Dussaillant (M)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.

Nadine Cerf-Bensussan (N)

Laboratoire d'immunité intestinale, Paris, France.
Université Paris Descartes - Sorbonne Paris Cité, Institut IMAGINE, Paris, France.

Habib Zouali (H)

Fondation Jean Dausset CEPH, Paris, France.

Fanny Daniel (F)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.

Frédérick Barreau (F)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.

Jean-Pierre Hugot (JP)

Centre de recherche sur l'inflammation, INSERM et Université de Paris, Paris, France.
Hopital Robert Debré, Asssitance Publique Hôpitaux de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH